{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-107253","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-09-14T11:12:01+00:00","discovered_at":"2026-09-14T11:15:08.610520+00:00","generated_at":"2026-09-14T11:15:17.936845+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Armata gets FDA Breakthrough Therapy designation for AP-SA02 in S. aureus bacteremia","bullets":["FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.","Designation based on Phase 1b/2a diSArm data: 100% of AP-SA02 patients maintained clinical response vs 75% on placebo at day 28.","AP-SA02 dosing every 6h for 5 days was well tolerated; no serious adverse events attributed to the drug.","AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations from the FDA.","CEO Deborah Birx cites potential to become first antibacterial approved on superiority to standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-107253","json":"https://secwatch.observer/filing/0001104659-26-107253.json","markdown":"https://secwatch.observer/filing/0001104659-26-107253.md","text":"https://secwatch.observer/filing/0001104659-26-107253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/0001104659-26-107253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/tm2625289d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T11:15:17.936845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}